Age distribution of human papillomavirus infection and cervical neoplasia reflects caveats of cervical screening policies
Authors:
Open Access
- 8 July 2009
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 126 (1) , 297-301
Abstract
Although a second age‐related peak of human papillomavirus (HPV) infection is observed in many populations, it does not seem to have any impact on cervical screening policies. We examined the age‐specific prevalence of HPV infection among 2,604 women enrolled for cervical screening and correlated the age at diagnosis of 2,491 cervical intraepithelial neoplasia Grade 2/3 (CIN2/3) lesions and 801 invasive cervical cancers (ICC). Two peaks of HPV infection were detected at 26–30 and 46–50 years, respectively. The first infection peak was followed by a CIN2/3 peak and an ICC peak at 5–15 and 15 years later, respectively. The second infection peak was followed by an ICC peak 20 years later, but strikingly no CIN2/3 peak was detected in between and thus eliminated an opportunity of treating the lesions at preinvasive stages. The most plausible explanation is that women at the expected second CIN2/3 peak (50–65 years) are not having Pap smears under the current opportunistic screening program. Furthermore, women of this age may have physiological retraction of the transformation zone, and CIN lesions may remain undetected if an adequate Pap smear sample is not obtained. To combat this problem, the screening program in Hong Kong needs to focus on women aged 50 years and older and a mop‐up screening up to 75 years is necessary. Bimodal peaks of HPV infection and cervical cancer are seen in many countries and the analysis of population‐specific age distribution of CIN2/3 should be an integral exercise in evaluating the effectiveness of a screening program.Keywords
This publication has 22 references indexed in Scilit:
- HPV Screening for Cervical Cancer in Rural IndiaNew England Journal of Medicine, 2009
- Prevalence of oncogenic human papillomavirus infection in an organised screening population in FinlandInternational Journal of Cancer, 2008
- Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sampleCancer, 2008
- Human papillomavirus DNA detection in ThinPrep Pap test vials is independent of cytologic sampling of the transformation zoneGynecologic Oncology, 2007
- Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysisThe Lancet Infectious Diseases, 2007
- Variations in the age‐specific curves of human papillomavirus prevalence in women worldwideInternational Journal of Cancer, 2006
- Relationships of Human Papillomavirus Type, Qualitative Viral Load, and Age with Cytologic AbnormalityCancer Research, 2006
- Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong KongJournal of Public Health, 2004
- Effectiveness and Efficiency of Opportunistic Cervical Cancer ScreeningMedical Care, 2004
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003